What's Happening?
Tensions have escalated between the American Diabetes Association (ADA) and several editors of its flagship journal, Diabetes Care, leading to a boycott of ADA activities. The dispute stems from the ADA's handling of a protest at its June conference in New
Orleans. Five researchers, including Steven Kahn, editor-in-chief of Diabetes Care and professor of medicine at the University of Washington, were ejected from the meeting for distributing copies of a Diabetes Care editorial on funding cuts. The editorial was distributed outside a hall where National Institutes of Health director Jay Bhattacharya was scheduled to speak. On September 1, the ADA announced the results of an independent review, which concluded that the attendees were removed due to violations of the conference's code of conduct, not because of the content they were distributing. However, Kahn and other editors have dismissed this review as a 'sham' and initiated a boycott of all ADA activities, including manuscript review for its journals. The editors placed a notice on the Diabetes Care submission page announcing the suspension of editorial review for new manuscripts, though this message was later removed and replaced with a banner from the ADA stating that operations continue without interruption.
Why It's Important?
This boycott by the editorial leadership of Diabetes Care, a prominent journal in clinical diabetes research, signifies a significant internal conflict within the American Diabetes Association. The dispute highlights concerns among professional members regarding the ADA's leadership structure and its representation of their interests. The suspension of manuscript review for new submissions to Diabetes Care could disrupt the dissemination of critical research in the field of diabetes, potentially delaying advancements in patient care and scientific understanding. The incident also raises questions about academic freedom and the right to protest within scientific conferences, particularly when the protest involves issues directly relevant to the scientific community, such as funding cuts. The public nature of this disagreement, with statements and counter-statements appearing on journal websites and social media, could damage the ADA's reputation and its ability to effectively serve its mission of supporting people with diabetes and advancing research.
What's Next?
The boycott by the editorial leadership of Diabetes Care is set to continue until the ADA Board of Directors allows a formal review of the organization's overall structure and function, led by an independent academic leader. This review is intended to ensure the ADA properly represents its professional membership. The ADA, however, has stated that its work and commitments continue without interruption, including the active acceptance and review of manuscripts across all its journals. This indicates a standoff between the boycotting editors and the ADA leadership. The situation could lead to further resignations from editorial boards or other professional roles within the ADA if the demands for an independent review are not met. The long-term impact on the journal's operations and the ADA's standing within the diabetes research community will depend on how this conflict is resolved, potentially through negotiations or further actions by either side. The incident may also prompt other professional organizations to review their policies regarding protests and member engagement.
Beyond the Headlines
This conflict within the American Diabetes Association reflects broader tensions that can arise in large professional organizations when leadership decisions are perceived to diverge from the interests or values of its members. The incident underscores the delicate balance between maintaining organizational order and upholding principles of academic freedom and open discourse. The use of a journal's editorial functions as a tool for protest highlights the significant influence that academic publications hold within their respective fields. It also brings to light the potential for internal governance issues to impact the core mission of an organization, in this case, the advancement of diabetes research and care. The outcome of this dispute could set a precedent for how similar conflicts are managed in other scientific and medical associations, influencing future policies on member engagement, protest, and leadership accountability.
